Critically, in either the autocrine or paracrine configuration, the synthetic IL-2 circuit did not cause a reduction in the contralateral NY-ESO+/GFP− tumor (lacking the synNotch ligand), highlighting the precisely targeted impact of the synthetic IL-2 circuit. The gene discussed is IL2; the disease is neoplasm.